For decades, maleimide chemistry has been the workhorse of cysteine-based Antibody-Drug Conjugate (ADC) conjugation. However, as the field matures, the limitations of this “standard” approach have become impossible to ignore. Specifically, the retro-Michael deconjugation—where the payload prematurely detaches and transfers to plasma proteins like albumin—remains a significant hurdle for stability and safety.

At SigutLabs, we are seeing a shift toward more robust alternatives, with 2-methyl(sulfonyl)pyrimidine warheads leading the charge.

The Mechanism: SNAr vs. Michael Addition

What makes this chemistry a game-changer? It comes down to the fundamental reaction pathway:

• Traditional Maleimide: Reacts via Michael addition. While efficient, this reaction is reversible, leading to the dreaded “retro-Michael” instability in the bloodstream.

• 2-methyl(sulfonyl)pyrimidine: Reacts via Nucleophilic Aromatic Substitution (SNAr). This pathway results in the formation of a stable aryl thioether bond.

By utilizing SNAr the retro-Michael problem is effectively eliminated. The result is a conjugate that stays together in systemic circulation, ensuring the payload is delivered to the tumor rather than being “dropped” into the plasma.

Clinical Proof of Concept

This isn’t just a theoretical improvement; it is already proving its worth in advanced clinical and preclinical programs. Two standout examples include:

• SKB264 (MK-2870): An anti-TROP2 ADC that utilizes a 2-methyl(sulfonyl)pyrimidine warhead to enhance linker stability, offering a clear advantage over traditional maleimide-based platforms.

• The TMALIN Platform (e.g., YL217): Developed by Medilink Therapeutics, this platform relies on proprietary 2-methyl(sulfonyl)pyrimidine chemistry for site-specific thiol coupling. With several programs currently in the clinic, it highlights the scalability and reliability of this approach.

Powering the Next Wave of ADC Innovation

Moving beyond maleimides is essential for the next generation of successful clinical candidates. At SigutLabs, we actively support the evolution of these next-gen warheads.

Whether you are looking to explore SNAr-based conjugation or require the synthesis of complex, site-specific linker-payload systems, our team is equipped to handle the most challenging chemistries in the ADC space.

Ready to upgrade your conjugation strategy? Connect with us at SigutLabs and let’s discuss how we can synthesize your preferred cysteine-reactive warheads.